Colorado BioScience Association Applauds Expansion by Novartis Company AveXis to Longmont

April 1, 2019


AveXis, a Novartis company, announced the growth of its global advanced gene therapy manufacturing capacity with the acquisition of an advanced biologics therapy facility in Longmont, Colo., formerly owned by AstraZeneca. In a company news release, AveXis officials indicated the Colorado facility will be the company’s fourth location in the U.S. involved in manufacturing AveXis gene therapies and the company intends to hire all 150 employees who previously worked at the campus.

Statement from Jennifer Jones Paton, president and CEO of CBSA, on the Novartis purchase of an advanced biologics therapy manufacturing campus in Longmont.

“We’re pleased to welcome AveXis and its team to Colorado. Our state is recognized as a growing bioscience hub and respected for our collaborative and supportive business climate. You’re joining more than 720 innovative bioscience companies and organizations dedicated to developing treatments and therapies that improve patients’ lives.”

“The AveXis decision to purchase the advanced biologics therapy manufacturing campus in Longmont highlights the infrastructure available for bioscience companies in Colorado and the access to an educated and experienced workforce.”

“Colorado BioScience Association looks forward to working with AveXis leaders now and in the future as the company grows in our state.”

Read the full AveXis news announcement.

Media Contacts:

Sheliah Reynolds

Primavera Group for Colorado BioScience Association

(720) 289-4739

Categories: Ecosystem News